Weekly Policy Blog: PDAB Deems Trikafta “Not Unaffordable” in First Affordability Decision

On Friday, December 8, the Colorado Prescription Drug Affordability Board (PDAB or Board) completed its first affordability review and unanimously voted that the selected drug, a cystic fibrosis drug...

Learn More

Weekly Policy Blog: Congratulations to CBSA’s 2023 Legislators of the Year 

On November 15, 2023, CBSA held its 20th Annual Awards Celebration presented by AGC Biologics. This annual celebration highlights the spirit and drive of Colorado’s vibrant life sciences ecosystem, br...

Learn More

Weekly Policy Blog: Join CBSA in Asking Congress to Address the R&D Tax Now 

Join CBSA in asking Congress to support leading-edge health innovation by American life sciences companies. We are asking Congress to remove a “tax on innovation” by restoring the immediate expensing...

Learn More

Weekly Policy Blog: Opposition to CMS’ Proposed Medicaid Drug Rebate Program (MDRP) Rule

CBSA and other members of the Council of State Bioscience Associations (CSBA) have submitted a letter to the Centers for Medicare & Medicaid Services (CMS) expressing our deep concern with a recen...

Learn More

Weekly Policy Blog: CBSA Has Concerns About Inconsistency of Preliminary Data Review Process for Drugs Under Affordability Review by PDAB 

CBSA has serious concerns about the Colorado Prescription Drug Affordability Board’s inconsistent approach to the preliminary data review process for drugs under affordability review in the first coho...

Learn More

Weekly Policy Blog: USITC Report Released on TRIPS COVID-19 IP Waiver Expansion

In June 2022, World Trade Organization (WTO) member states agreed to waive certain WTO intellectual property protections for COVID-19 vaccines. The U.S. Trade Representative (USTR) has been considerin...

Learn More

Weekly Policy Blog: CBSA Co-Hosts Facility Tours for State Legislators and Local Leaders 

Weekly Policy Blog: CBSA Co-Hosts Facility Tours for State Legislators and Local Leaders  This month CBSA partnered with both Terumo Blood and Cell Technologies (Terumo BCT) and AGC Biologics to host...

Learn More

Weekly Policy Blog: CBSA Urges Congress to Pass the PASTEUR Act 

Earlier this month, CBSA participated in PASTEUR Advocacy Day, joining Biotechnology Innovation Organization (BIO) and other organizations, including Infectious Diseases Society of America, Cystic Fib...

Learn More

Efforts to Control Prescription Drug Pricing Harm Collaborative Work to Advance Patient Care with Health Innovations

Elyse Blazevich, President & CEO, Colorado BioScience Association Colorado’s life sciences community and our state leaders share an unwavering commitment to improving patient lives and making sure...

Learn More

Weekly Policy Blog: FDA Guidances on 510(k) Submissions; Actuarial Review of Biomarker Testing Coverage Bill 

FDA Issues Three Guidances on Premarket Notification [510(k)] Program  On September 7, 2023, the U.S. Food and Drug Administration’s (FDA’s) Center for Devices and Radiological Health (CDRH) issu...

Learn More